Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase 1/2 2Phase NA 1Phase 4 1

Status

Terminated 12Recruiting 12Completed 10Not yet recruiting 9Active not recruiting 8Unknown 4Withdrawn 3Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 2Thoracic 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 2Thymoma 1Recurrence 1Leukemia, Myeloid, Acute 1

Interventions

Cisplatin 270Oxaliplatin 195Carboplatin 191Capecitabine 184Docetaxel 178apatinib 164Paclitaxel 163Bevacizumab 159Gemcitabine 156Radiotherapy 147camrelizumab 146Fluorouracil 144Cyclophosphamide 126Irinotecan 120Drug Therapy 119sintilimab 108Etoposide 99anlotinib 90S 1 (combination) 89Leucovorin 86pembrolizumab 85toripalimab 78Pemetrexed 78Doxorubicin 77tislelizumab 76Dexamethasone 71Trastuzumab 65Neoadjuvant Therapy 65Rituximab 62Cetuximab 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Unknown × selinexor × Clear all
NCT04877275 2023-12-06

ATG-010(Selinexor) in Combination With Chemotherapy in RRMM

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Unknown
50 enrolled
Plasma cell

Multiple Myeloma

NCT05951855 2023-07-19

Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

The First Affiliated Hospital of Soochow University

Phase 2 Unknown
42 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT04941937 2023-02-27

Selinexor in Combination With Immunomodulator (Thalidomide/Pomalidomide/Lenalidomide)in RRMM

Shanghai Changzheng Hospital

Phase 2 Unknown
90 enrolled
Plasma cell

Multiple Myeloma

NCT03466827 2018-03-15

TET-SEL

Rigshospitalet, Denmark

Phase 2 Unknown
25 enrolled
Thoracic

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚔